Generate Biomedicines, Inc. (GENB)
$12.52+2.12%Close
SELL
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $1.6B
- Beta
- -0.14
- P/E (TTM)
- -11.81
- Short % float
- 13.47%
- Days to cover
- 5.8
- SI change
- +3.3%
- 1W
- -7.74%
- 1M
- -22.67%
- vs SPY 1W
- -7.60%
- vs SPY 1M
- -25.17%
Industry peers
FMP comparable companies · ranked by market cap
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 5
- VALUE
- 3
- GROWTH
- 17
- GARP
- 5
- TYPE
- Balanced
Composite of Value · Growth · GARP
ROIC-65.3%
REV YoY-
ROE-108.8%
EPS YoY-
ROA-22.9%
GROSS76
OP-1003
NET-951
[VALUATION]
P/E TTM-11.81
P/E FWD-
SECTOR PE20.48
INDUSTRY PE13.99
P/B3.52
P/FCF-
EV/EBITDA-12.29
EV/EBIT-
PEG-
FCF YIELD-
RISK
INT COV-
D/E13.73
ALTMAN Z-
CURR RATIO8.30
ND/EBITDA-
BETA-0.14
Company news
FAQ
- What is LOPJLB’s current signal on GENB?
- LOPJLB’s latest quantitative signal on Generate Biomedicines, Inc. (GENB) is SELL. Signals are updated daily.
- What market regime is GENB in?
- LOPJLB classifies each ticker into BULL, RECOVERY, BEAR, or CRISIS regimes using a Hidden Markov Model.
- What does Generate Biomedicines, Inc. (GENB) do?
- Generate Biomedicines, Inc. is a U.S.-based company pioneering generative biology, leveraging machine learning for the discovery and advancement of novel protein therapeutics. Their core approach involves developing drugs using protein-based modalities. The company's pipeline includes several key candidates: GB-0895, an investigational long-acting anti-TSLP monoclonal antibody designed for bi-a…